{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:24:07Z","timestamp":1787408647853,"version":"build-2736575974"},"reference-count":57,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated. PH is classified into five groups (WHO Groups 1\u20135) based on etiology and pathophysiology. Group 1 PH, known as pulmonary arterial hypertension (PAH), has seen recent therapeutic advances with life\u2010extending treatments, including a new therapeutic option that targets the underlying vascular abnormalities. PAH treatment guidelines now emphasize early diagnosis, risk stratification, and targeting multiple pathophysiologic pathways with upfront combination therapy. In contrast to PAH treatment, strategies for other forms of PH remain limited and focus on managing pathophysiologic processes outside the pulmonary vasculature, including left heart disease (Group 2), lung disease and\/or hypoxia (Group 3), or pulmonary artery obstructions (Group 4). Nevertheless, advances in research have introduced novel therapeutic targets and investigational agents, offering hope for future expanded treatment options. In this review, we explore recent advances in PH treatments, highlighting the developments poised to expand the therapeutic landscape for this complex disease.<\/jats:p>","DOI":"10.1111\/cts.70685","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:12:14Z","timestamp":1785499934000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification"],"prefix":"10.1111","volume":"19","author":[{"given":"Surya","family":"Ayalasomayajula","sequence":"first","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ednan K.","family":"Bajwa","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra G.","family":"Cornell","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Loureiro","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Kim","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Richmond","family":"DiBello","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sterner","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9000-0431","authenticated-orcid":false,"given":"Islam R.","family":"Younis","sequence":"additional","affiliation":[{"name":"Merck &amp; Co., Inc.  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879\u20102022"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324\u20102024"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325\u20102024"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2000348"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcchd.2025.100571"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14330"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.03.029"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0205\u20102022"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.033"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010025\u201003297\u20102"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02356\u20102021"},{"key":"e_1_2_9_14_1","unstructured":"Pharmaceutical Technology \u201cPF\u201007868489 by Pfizer for Pulmonary Arterial Hypertension: Likelihood of Approval \u201dhttps:\/\/www.pharmaceutical\u2010technology.com\/data\u2010insights\/pf\u201007868489\u2010pfizer\u2010pulmonary\u2010arterial\u2010hypertension\u2010likelihood\u2010of\u2010approval\/?utm_source=lgp5\u2010loa&utm_medium=24\u2010274517&utm_campaign=recommended\u2010articles."},{"key":"e_1_2_9_15_1","unstructured":"Fierce Biotech \u201cNovartis Channels Gargamel Terminating Midphase SMURF1 Trial \u201dhttps:\/\/www.fiercebiotech.com\/biotech\/novartis\u2010channels\u2010gargamel\u2010terminating\u2010third\u2010midphase\u2010smurf1\u2010trial\u2010quick\u2010succession."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01370\u20102024"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.150.suppl_1.4139216"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202405\u20100914SO"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2017.02.016"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-02994-w"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010022\u201011435\u2010x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz5660"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010024\u201002058\u20109"},{"key":"e_1_2_9_25_1","unstructured":"Merck Sharp & Dohme LLC \u201cWINREVAIRTM(sotatercept\u2010csrk) for Injection for Subcutaneous Use \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761363s008lbl.pdf."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213558"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415160"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508170"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00105914"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01886\u20102017"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2527"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01200\u20102024"},{"key":"e_1_2_9_34_1","unstructured":"U.S. Food and Drug Administration \u201cYUTREPIA (treprostinil) Inhalation Powder for Oral Inhalation \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213005s000lbl.pdf."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00172\u20102024"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01294\u20102024"},{"key":"e_1_2_9_37_1","unstructured":"U.S. Food and Drug Administration \u201cADEMPAS (riociguat) \u201dhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/204819s015lbl.pdf."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107\u20102023"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(24)00072\u20109"},{"key":"e_1_2_9_40_1","unstructured":"Gossamer Bio \u201cGossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension \u201dhttps:\/\/ir.gossamerbio.com\/news\u2010releases\/news\u2010release\u2010details\/gossamer\u2010bio\u2010announces\u2010topline\u2010results\u2010phase\u20103\u2010prosera\u2010study."},{"key":"e_1_2_9_41_1","unstructured":"Gossamer Bio \u201cGossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update \u201dhttps:\/\/ir.gossamerbio.com\/news\u2010releases\/news\u2010release\u2010details\/gossamer\u2010bio\u2010announces\u2010first\u2010quarter\u20102026\u2010financial\u2010results\u2010and."},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/life15030430"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040496"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.126.079918"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13523"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.15203"},{"key":"e_1_2_9_47_1","unstructured":"Fierce Biotech \u201cAstraZeneca Relaxed About Relaxin Drug's Poor Efficacy in Phase 2 Heart Failure Trial \u201dhttps:\/\/www.fiercebiotech.com\/biotech\/astrazeneca\u2010drops\u2010heart\u2010failure\u2010asset\u2010over\u2010phase\u20102\u2010efficacy\u2010data."},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/eschf\/xvaf007"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2025.06.009"},{"key":"e_1_2_9_50_1","unstructured":"Gossamer Bio \u201cAbout Seralutinib \u201dhttps:\/\/www.gossamerbio.com\/science\/seralutinib\/."},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S372239"},{"key":"e_1_2_9_52_1","unstructured":"Insmed \u201cInsmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once\u2010Daily Therapy in Patients with Pulmonary Arterial Hypertension \u201dhttps:\/\/investor.insmed.com\/2025\u201006\u201010\u2010Insmed\u2010Announces\u2010Positive\u2010Topline\u2010Results\u2010from\u2010Phase\u20102b\u2010Study\u2010of\u2010Treprostinil\u2010Palmitil\u2010Inhalation\u2010Powder\u2010TPIP\u2010as\u2010Once\u2010Daily\u2010Therapy\u2010in\u2010Patients\u2010with\u2010Pulmonary\u2010Arterial\u2010Hypertension."},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311737"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12271"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020962960"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.12.012"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0006\u20102025"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20102600(24)00425\u20109"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T13:38:16Z","timestamp":1787405896000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/cts.70685"],"URL":"https:\/\/doi.org\/10.1111\/cts.70685","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2025-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70685"}}